Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Qiagen Reports Preliminary Q1 Revenue Growth of 9 Percent

Qiagen Reports Preliminary Q1 Revenue Growth of 9 Percent

Apr 09, 2020
|
staff reporter

NEW YORK – Qiagen said on Thursday that its first quarter revenues and earnings per share are expected to be significantly higher than previously issued guidance, primarily due to sales of products used in COVID-19 testing.

For the three months ended March 31, 2020, Qiagen reported preliminary revenue growth of 9 percent at constant exchange rates, compared to a prior outlook, issued on Feb. 4, of approximately 2 percent to 3 percent growth.

Sales reflected "very significant" demand for products used in COVID-19 testing against weaker customer demand in other product areas.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

To Get Back Going

The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.

UK COVID-19 Disparities Report

A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.

Trials Figure Out Paths Forward Despite Pandemic

NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.

Nature Papers Present CRISPR-Cas3 System to Make Large Genomic Deletions, Molecular Mechanisms of Chemoresistance in ALL

In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.

Oct
28
Featured Webinar

How Low Can You Go? Reduce Breeding Costs with an Optimized Genotyping and Analysis Strategy

Sponsored by
NRGene

Molecular breeding methods such as genomic selection and genome-wide association studies often require high-density genotypic data from many samples, but the cost and complexity of genotyping at this scale may be prohibitive.

Oct
29
Featured Webinar

How to Train Your DRAGEN for Pathology Informatics

Sponsored by
Illumina

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

Nov
03
Featured Webinar

A Streamlined Targeted NGS Workflow for Comprehensive Genomic Profiling of Different Tumor Samples

Sponsored by
Agilent

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05
Featured Webinar

Beyond Traditional Biopsy for Esophageal Cancer: Novel Sampling Methods to Improve Patient Care

Sponsored by
Roche

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

What's Popular?

In Molecular Diagnostics

  1. Thermo Fisher Scientific Q3 Revenues Soar 36 Percent

  2. Abbott Q3 Diagnostics Revenues Increase 38 Percent

  3. Invitae, Pacific Biosciences Collaborate on NGS-Based Pediatric Epilepsy Testing

  4. Danaher Q3 Revenues Up 35 Percent

  5. BD, CerTest Biotec Get CE-IVD Mark for Combination COVID-19, Influenza, RSV Test on BD Max

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.